Lexaria Bioscience Corp (LEXX)

[Shawking]

I see that Gillian Dines, Chief Science Officer of Juvenescence, once worked for Jazz Pharma. Jazz Pharma now owns Epidiolex which may benefit from using DehydraTECH to improve the bioavailability.
'Before joining Juvenescence she was Senior Vice President and Head of Research and Early Development at Jazz Pharmaceuticals. In this role she led integration and organisational restructuring to build a novel pipeline and capabilities in R&D following the acquisition of GW Pharma where she was Head of R&D Operations.'